Public Works and Government Services Canada | Travaux publics et Services gouvernementaux Canada

RETURN BIDS TO:
RETOURNER LES SOUMISSIONS À:

Bid Receiving - PWGSC / Réception des soumissions - TPSGC
11 Laurier St./ 11 rue, Laurier
Place du Portage, Phase III
Core 0B2 / Noyau 0B2
Gatineau, Québec K1A 0S5
Bid Fax: (819) 997-9776

LETTER OF INTEREST
LETTRE D'INTÉRÊT

Title - Sujet
MULTIDRUG IMMUNOASSAY FIELD TEST

Solicitation No. - N° de l'invitation	Date
47419-193304/A	2018-09-14
Client Reference No. - N° de référence du client	**GETS Ref. No. - N° de réf. de SEAG**
1000343304	PW-$$PV-873-75476
File No. - N° de dossier	**CCC No./N° CCC - FMS No./N° VME**
pv873.47419-193304	

Solicitation Closes - L'invitation prend fin
at - à 02:00 PM
on - le 2018-10-26

Time Zone
Fuseau horaire
Eastern Daylight Saving Time EDT

F.O.B. - F.A.B. Specified Herein - Précisé dans les présentes
Plant-Usine: ☐ **Destination:** ☐ **Other-Autre:** ☑

Address Enquiries to: - Adresser toutes questions à:	Buyer Id - Id de l'acheteur
Shannahan, Cassandra	pv873
Telephone No. - N° de téléphone	**FAX No. - N° de FAX**
(819) 420-1068 ( )	(819) 956-3814

Destination - of Goods, Services, and Construction:
Destination - des biens, services et construction:

Specified Herein
Précisé dans les présentes

Comments - Commentaires

Instructions: See Herein

Instructions: Voir aux présentes

Vendor/Firm Name and Address
Raison sociale et adresse du fournisseur/de l'entrepreneur

Delivery Required - Livraison exigée	Delivery Offered - Livraison proposée
See Herein	

Vendor/Firm Name and Address
Raison sociale et adresse du fournisseur/de l'entrepreneur

Telephone No. - N°de téléphone
Facsimile No. - N° de télécopieur

Name and title of person authorized to sign on behalf of Vendor/Firm (type or print)
Nom et titre de la personne autorisée à signer au nom du fournisseur/ de l'entrepreneur (taper ou écrire en caractères d'imprimerie)

Signature **Date**

Issuing Office - Bureau de distribution
Scientific, Medical and Photographic Division / Division de l'équipement scientifique, des produits photographiques et pharmaceutiques
11 Laurier St./ 11 rue, Laurier
6A2, Place du Portage
Gatineau, Québec K1A 0S5

Canada

LETTER OF INTEREST (LOI)

MULTIDRUG IMMUNOASSAY FIELD TEST

1. Background for this Letter of Interest (LOI)

The Canada Border Services Agency (CBSA) has a requirement to investigate the use of multiple drug ("multidrug") immunoassay field tests for the presumptive identification of illicit drugs. For these purposes, a multiple drug immunoassay field test is defined as a single test that can identify three or more drugs at once.

2. Purpose of this Letter of Interest

The purpose of this LOI is to allow stakeholders and manufacturers an opportunity to provide information on multidrug immunoassay tests currently available that may benefit the CBSA.

2.1 The objectives of the LOI are:

A) to identify field detection immunoassay tests available for presumptive screening of illicit drugs;
B) to identify the advantages, limitations and technology gaps of the immunoassay tests;
C) to conduct a laboratory analysis of selected immunoassay tests against manufacturer claims and CBSA field requirements.

3. Nature of the LOI

A Letter of Interest (LOI) is used when detailed information and feedback is required from suppliers. Such requests might outline a potential requirement and request suppliers to describe their ability to satisfy the requirement. This LOI contains background and technical information.

4. Note to Potential Respondents

This is not a bid solicitation. This LOI will not result in the award of any contract or lead to any development funding initiative. Potential suppliers of any goods described in this LOI should not reserve stock as a result of any information contained in the LOI, nor will this LOI result in the creation of any source list. Therefore, whether or not any potential supplier responds to this LOI will not preclude that supplier from participating in any future procurement. The procurement of any of the goods described in this LOI will not necessary follow this LOI. This LOI is simply intended to solicit feedback from industry with respect to the matters described in this LOI.

4.1 Response Costs

Canada will not reimburse any respondent for expenses incurred in responding to this LOI.

5. Nature and Responses Requested

Use of Responses: Responses will not be formally evaluated. However, the responses received may be used by Canada to develop or modify procurement strategies or any draft documents contained in this LOI. Canada will review all responses received by the LOI closing date. Canada may, in its discretion, review responses received after the LOI closing date.

Review Team: A review team composed of representatives of Canada will review the responses. Canada reserves the right to hire any independent consultant, or use any Government resources that it considers necessary to review any response.

Confidentiality: Respondents should mark any portions of their response that they consider proprietary or confidential. Canada will handle the responses in accordance with the *Access to Information Act*.

Follow-up Activity: Canada may, at its discretion, meet with respondents who indicate in their responses that they wish to participate in a follow-up meeting. Such follow-up activity, if conducted, may include, but is not limited to, individual meetings and/or on-site demonstrations. Canada may, in its discretion, contact any respondents to follow up with additional questions, for clarification of any aspect of a response or to arrange an individual meeting and/or on-site demonstration.

Testing: Respondents are requested to identify whether they are willing to provide samples of their tests for testing purposes (see section 10, question 15 herein). If a respondent agrees to provide samples, they may be contacted by a representative of CBSA within 10 weeks of LOI closing to make arrangements for shipping. All costs associated with sending samples to CBSA will be the sole responsibility of the respondent. Testing will be conducted by CBSA at its Science and Engineering Directorate in Ottawa, ON. Respondents will not be provided with a copy of the test results. Samples will be disposed of after testing is complete.

6. Format of Responses Requested

Cover Page: If the response includes multiple volumes, respondents are requested to indicate on the front cover page of each volume the title of the response, the solicitation number, the volume number and the full legal name and address of the respondent.

Title Page: The first page of each volume of the response, after the cover page, should be the title page, which should contain:

- the title of the respondent's response and the volume number;
- the name and address of the respondent;
- the name, address and telephone number of the respondent's contact;
- the date; and
- the LOI number.

Numbering System: Respondents are requested to prepare their response using a numbering system corresponding to the one in this LOI. All references to descriptive material, technical manuals and brochures included as part of the response should be referenced accordingly.

Note: Respondents are asked to include, as an appendix, a picture of their multidrug immunoassay field test, descriptive material, technical manuals and brochures.

Number of Copies: Respondents are requested to submit one softcopy, in PDF format, of their response.

7. Enquiries

Respondents with questions regarding this Letter of Interest may direct their enquiries, preferably via email, to:

Cassandra Shannahan
Public Services and Procurement Canada
11 Laurier Street, 6A2, Phase III
Place du Portage, Gatineau, Quebec, K1A 0S5

Telephone: (819) 420-1068
Facsimile: (819) 956-3814
Email address: cassandra.shannahan@pwgsc-tpsgc.gc.ca

8. Submission of Responses

Time and Place for Submission of Responses: Respondents should send responses electronically via e-mail to the Contracting Authority's address identified herein by the date specified on the front page of the LOI.

Responsibility for Timely Delivery: Each respondent is solely responsible for ensuring its response is delivered on time to the correct location.

9. Closing Date

Responses to this Letter of Interest will be accepted any time until 14:00 EST, October 26, 2018.

10. Contents of this LOI

To enable this assessment, interested distributors and manufacturers are asked to provide answers to the following questions:

1. How many drugs can be identified simultaneously with a single test?

2. What drugs can be detected and identified using your multidrug immunoassay field test? If you have different multidrug tests, please list each separately with the drugs detected for each of the different multidrug tests.
3. How are the results interpreted on your multidrug immunoassay field test?
4. What is the analysis time for your multidrug immunoassay field test (i.e., how long does it take to run a sample)? Explain.
5. What is the shelf life of your multidrug immunoassay field test?
6. What is the approximate cost of your multidrug immunoassay field test?
7. Can your multidrug immunoassay field test only be used for drug detection in urine? If not, please provide additional information.
8. What is the sample preparation required from the user of your multidrug immunoassay field test?
    a) What sample preparation is required if the sample is a powder?
    b) What sample preparation is required if the sample is a liquid?
    c) What sample preparation is required if the sample is adsorbed onto support (e.g., blotter paper)?
    d) Are there any matrices that are not suitable for your field test?
9. What are the drug detection limits of your multidrug immunoassay field test?
10. Are there any known false positives (i.e., a test result which incorrectly indicates that a particular drug is present) with your multidrug immunoassay field test?
11. What is the operating temperature range of your multidrug immunoassay field test?
12. What is the storage temperature range of your multidrug immunoassay field test?
13. Has your multidrug immunoassay field test been used successfully in the field by law enforcement? Explain in detail, citing previous experience if possible.
14. Has law enforcement in Canada used your multidrug immunoassay field test?
15. Are you willing to send 50 units of your multidrug immunoassay field test to the Science and Engineering Directorate (Ottawa, Ontario) at your cost for testing?

Appendix:
Respondents are asked to include, as an appendix, a picture of their multidrug immunoassay field test(s), any descriptive material, technical manuals, links to online material and brochures.